We conclude that targeting FGFR4 in the liver to activate the intestinal FXR-FGF15 axis may be a promising strategy for the treatment of NAFLD and metabolic dysfunction. The gene discussed is FGFR4; the disease is metabolic dysfunction-associated steatotic liver disease.